Cellebrite DI Ltd. Reports 20% Revenue Growth and 34% Increase in Adjusted EBITDA for Q1 2025

Reuters
05-14
<a href="https://laohu8.com/S/CLBT">Cellebrite</a> DI Ltd. Reports 20% Revenue Growth and 34% Increase in Adjusted EBITDA for Q1 2025

Cellebrite DI Ltd. reported its financial results for the first quarter of 2025, highlighting a revenue increase to $107.5 million, marking a 20% growth primarily driven by a 21% increase in subscription revenue. The company's Annual Recurring Revenue $(ARR)$ grew by 23%, reaching $408.0 million. Adjusted EBITDA for the quarter stood at $23.7 million, reflecting a 34% year-over-year increase, with an adjusted EBITDA margin of 22.0%. In recent business developments, Cellebrite introduced its Spring 2025 Release on May 6, 2025, which features the new Cellebrite Cloud and AI-powered innovations across its product portfolio. These advancements are designed to enhance digital workflows, expedite investigations, and boost operational productivity and efficiency. The company is also advancing its Case-to-Closure Platform into the next-generation Digital Investigation Platform as more customers adopt a broader range of its integrated solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellebrite DI Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450878-en) on May 14, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10